UroGen Pharma Ltd. URGN

UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...

For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at […]

UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics in targeted tissue sites for extended periods, the company addresses the significant clinical limitations of systemic toxicity and rapid clearance common in traditional cancer treatments. Its underlying […]

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) f

PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September. Wells Fargo 21st Annual Healthcare Conference Date / Time:September 9th, at 3:00 PM ETFormat:Fireside ChatLocation:Boston, MAWebcast Link:Here Cantor Global Healthcare Conference 2026 Date / T

IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.

Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platformAgreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug UGN-103 (mitomycin) for intravesical solution. UGN-103 is a next-generation mitomycin formulation being developed for the treatment of adults with

Why UroGen Pharma Stock Is Back in Focus After Q2 2026 Earnings UroGen Pharma (URGN) is back on investors radar after reporting second quarter 2026 results on 5 August, highlighted by higher reported sales and a smaller net loss for both the quarter and first half. The company reported Q2 sales of US$72.46 million with a net loss of US$14.35 million, and first half sales of US$123.42 million with a net loss of US$37.93 million, which may be reshaping sentiment around the stock. See our latest...

UroGen Pharma Ltd. reported past second-quarter 2026 results showing sales of US$72.46 million versus US$24.22 million a year earlier, with net loss narrowing to US$14.35 million from US$49.94 million and basic loss per share from continuing operations improving to US$0.28 from US$1.05. Over the first half of 2026, sales almost tripled to US$123.42 million while the net loss roughly halved to US$37.93 million, suggesting meaningful operating leverage as revenue scales. Next, we’ll examine...